IL3抗体;IL3 Antibody—艾普蒂

+ +

•  

   

     Result: P15446 can detect IL3 by Western blotting.    

  
  

Interleukin-3 (IL-3) is a cytokine primarily involved in hematopoiesis, immune regulation, and inflammation. It is produced by activated T cells, mast cells, and stromal cells, and functions by binding to the IL-3 receptor (IL-3R), a heterodimer composed of α (CD123) and β (CD131) subunits. This interaction activates signaling pathways such as JAK-STAT, MAPK, and PI3K, promoting the survival, proliferation, and differentiation of hematopoietic stem cells, particularly myeloid lineages like mast cells, basophils, and megakaryocytes. Dysregulation of IL-3 signaling is implicated in allergic disorders, autoimmune diseases, and hematologic malignancies, including acute myeloid leukemia (AML).

IL-3 antibodies are tools or therapeutics designed to target IL-3 or its receptor. Research-grade antibodies are widely used in immunoassays (e.g., ELISA, flow cytometry) to quantify IL-3 levels or map its expression in physiological and pathological contexts. Therapeutic monoclonal antibodies (mAbs) or antibody-drug conjugates (ADCs) against CD123 (IL-3Rα) have gained attention for treating CD123-positive cancers, aiming to block IL-3-mediated survival signals or deliver cytotoxic payloads to malignant cells. Challenges include managing on-target off-tumor effects due to CD123’s expression on healthy hematopoietic cells. Recent advancements include bispecific antibodies and CAR-T therapies targeting IL-3R, though clinical efficacy and safety remain under investigation. Overall, IL-3 antibodies bridge basic research and translational medicine, offering insights into immune regulation and novel cancer treatment strategies.